Backed by Yale Cancer Center Research, FDA Approves New Immunotherapy Drug for Stomach Cancer

Article ID: 681592

Released: 22-Sep-2017 4:30 PM EDT

Source Newsroom: Yale Cancer Center

Expert Pitch
  • Credit: Yale Cancer Center

    Charles S. Fuchs, Yale Cancer Center

A drug whose clinical testing was led by Charles S. Fuchs, MD, MPH, director of Yale Cancer Center, has become the first immunotherapy treatment for advanced stomach cancer.

The drug, pembrolizumab (Keytruda®), was approved by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with advanced stomach cancer showing PD-L1 positive tumors. Pembrolizumab works by increasing the ability of the body’s immune system to help detect and fight tumor cells.

In 2017, an estimated 28,000 Americans will be diagnosed with stomach cancer.

http://yalecancercenter.org/patient/people/charles_fuchs.profile

 

 

 

 


Comment/Share





Chat now!